Search Results
Nov 24, 2025, 16:32 ET Alaska Air Group to webcast Goldman Sachs Industrials and Materials conference
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Air Group
Nov 24, 2025, 16:01 ET Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
More news about: Nuvalent, Inc.
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
prevalence of these signatures in mutation-negative leukemia (ABSTRACT 25-4127) Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P (ABSTRACT 25-1798) Harnessing repressive LEF1/β-catenin complexes to overcome
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 20, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alaska Air Group, Inc. - ALK
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alaska Air Group, Inc. ("Alaska Air" or the "Company") (NYSE: ALK). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Nov 19, 2025, 16:19 ET Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Forward-Looking
More news about: Nuvalent, Inc.
Nov 18, 2025, 23:50 ET Nuvalent Announces Pricing of Public Offering of Common Stock
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Cautionary
More news about: Nuvalent, Inc.
Nov 18, 2025, 05:40 ET Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence
increasing the demand for molecular testing platforms. Cancer treatment decisions are now routinely anchored in genomic alterations, such as EGFR, ALK, ROS1, BRCA1/2, BRAF, KRAS, HER2, and emerging biomarkers like MET exon 14 skipping, RET, NTRK fusions, and tumor mutational burden (TMB).
More news about: DataM Intelligence 4 Market Research LLP
Nov 17, 2025, 16:01 ET Nuvalent Announces Public Offering of Common Stock
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Cautionary
More news about: Nuvalent, Inc.
Nov 17, 2025, 06:30 ET Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
advanced ALK-positive NSCLC. Global enrollment in ALKOVE-1 remains ongoing for adult and adolescent patients with ALK-positive solid tumors other than NSCLC, and for adolescent patients with ALK-positive NSCLC. In this topline pivotal dataset for the TKI pre-treated ALK-positive
More news about: Nuvalent, Inc.
Nov 14, 2025, 16:01 ET Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
first-in-human Phase 1/2 clinical trial for patients with advanced ALK-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ALK-positive NSCLC patients who previously received at least one ALK TKI, or patients with other ALK-positive solid tumors who had been previously treated or for
More news about: Nuvalent, Inc.
Nov 13, 2025, 08:00 ET Ready, set, Italia! Alaska Airlines opens ticket sales for new nonstop flights between Seattle and Rome on spacious, widebody 787 Dreamliner aircraft
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Nov 12, 2025, 09:00 ET Alaska Air Group Announces Executive Appointments and Promotions within Alaska Airlines and Horizon Air Operations
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Nov 10, 2025, 08:00 ET Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
today shared the interim Phase II clinical data for its "first-in-class" Tosposertib (TU2218), a dual inhibitor against TGFβ type I receptor (TGFβRI /ALK5) and VEGFR2. The study evaluated Tosposertib in combination with MSD's Keytruda (pembrolizumab) as a first-line therapy for patients with recurrent/metastatic(r/m)
More news about: TiumBio
Nov 04, 2025, 17:12 ET Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
More news about: Nuvalent, Inc.
Oct 30, 2025, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
quarter from our ALKOVE-1 trial of neladalkib in TKI pre-treated advanced ALK-positive NSCLC, and continue to progress ALKAZAR, our global Phase 3 randomized, controlled trial of neladalkib for TKI-naïve patients with advanced ALK-positive NSCLC." "Our commercial preparedness activities
More news about: Nuvalent, Inc.
Oct 29, 2025, 06:30 ET Alaska and Hawaiian Airlines Reach Major Integration Milestone: a Single Operating Certificate
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Oct 28, 2025, 07:00 ET Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
model with ALK-EML4 rearrangement. The combination of REQORSA and an ALK inhibitor led to longer survival in the mouse model. ALK-EML4 rearrangements occur in approximately 4% of all patients with NSCLC. We believe these positive data open a pathway for a potential future clinical trial in ALK-positive
More news about: Genprex, Inc.
Oct 27, 2025, 12:47 ET Alaska Airlines strengthens commitment to San Diego, Portland and Hawai'i with 13 new routes, and adds more flight frequencies across our network
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Oct 23, 2025, 20:41 ET Alaska Air Group reports third quarter 2025 results
SEATTLE, Oct. 23, 2025 /PRNewswire/ -- Alaska Air Group (NYSE: ALK) today reported financial results for the third quarter ending September 30, 2025. "Alaska's profitable quarter was powered by
More news about: Alaska Air Group
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
NRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
EML4-ALK fusion (Echinoderm microtubule-associated protein-like 4- Anaplastic Lymphoma Kinase) occurs in approximately 5% of NSCLC. Tumors bearing the fusion are sensitive to ALK Tyrosine Kinase Inhibitors (TKIs), that form the first and second line of treatment for these patients. However, ALK+ lung
More news about: Genprex, Inc.
Oct 18, 2025, 06:00 ET Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
characteristics of activity against ALK and ALK resistance mutations, brain penetrance, and avoidance of TRK inhibition associated with off-target CNS adverse events," saidChristopher Turner, M.D., Chief Medical Officer of Nuvalent. "These data highlight the potential for an ALK-selective inhibitor to
More news about: Nuvalent, Inc.
Oct 16, 2025, 10:30 ET Anvisa aprova nova indicação para durvalumabe da AstraZeneca que reduz em 32% o risco de recidiva no câncer de pulmão operável[1]
adultos com câncer de pulmão de não pequenas células (CPNPC) em estágio inicial, com possibilidade de cirurgia e sem mutações conhecidas nos genes EGFR ou ALK. O tratamento consiste em duas etapas: primeiro, a aplicação de durvalumabe com quimioterapia antes da cirurgia e, depois, a continuidade
More news about: AstraZeneca
Oct 14, 2025, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
the University of Michigan Rogel Cancer Center in October 2024 to study TUSC2, the tumor suppressor gene used in REQORSA, in combination with ALK-inhibitors in ALK-EML4 positive translocated lung cancer. Also in October 2024, Genprex announced its collaboration with
More news about: Genprex, Inc.
Oct 13, 2025, 17:31 ET Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight
20% of the global population. Leading allergic rhino-conjunctivitis companies, such as Immunotek, Merck, ALK-Abello, and others, are active in the allergic rhino-conjunctivitis market. The promising allergic rhino-conjunctivitis therapies
More news about: DelveInsight Business Research, LLP